Hansa Biopharma plans restructuring to strengthen long-term competitiveness and advance key deliverables
Lund, Sweden, 5 December 2023. Hansa Biopharma, “Hansa” (Nasdaq Stockholm: HNSA), announced today that it plans to restructure the organisation to better align and focus on key clinical development and commercial priorities. The planned restructuring would result in an approximately 20-25% reduction in the current workforce and will result in approximately 75-85 million SEK in annual savings when implemented. The restructuring is subject to negotiation with relevant trade unions. Søren Tulstrup, President and CEO, Hansa Biopharma said: “This planned restructuring is an important step in